April 6 (Reuters) - Praxis Precision Medicines Inc PRAX.O:
PRAXIS PRECISION MEDICINES ANNOUNCES POSITIVE RESULTS FROM THE EMBRAVE PART A TRIAL OF ELSUNERSEN IN PATIENTS WITH SCN2A EARLY-ONSET DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
PRAXIS PRECISION MEDICINES INC - ELSUNERSEN WELL-TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS UP TO 8 MG